Ranolazine roche bioscience

IDrugs

Volumn 2, Issue 12, 1999, Pages 1353-1362

  Jones, Richard ^a  

^a Trinity Cottage Killiney Hill   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747141363     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (125)

1. Overview of existing and future anti-ischaemic drugs. Massingham R, John G PROG PHARMACOL CLIN PHARMACOL 19908109-138.
2. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H J CARD1OVASC PHARMACOL 1992201 131-138
3. Clinical study showing the effects of ranolazine on exercise tolerance in 104 angina pectoris patients. Beneficial effects shown on tolerance without significant changes in hemodynamics.
4. Ranolazine. DRUGS FUTURE 1991 16 9 868
5. Ranolazine - A new drug with beneficial effects on renal preservation. Lodge JP, Lam T, Perry SL, Giles GR TRANSPLANTATION 1990 50 755-759
6. Overview of existing and future anti-ischaemic drugs.
7. Massingham R, John G PROG PHARMACOL CLIN PHARMACOL 19908109-138
8. Ranolazine. DRUGS FUTURE 199015 9 964-965
9. Free radical scavengers fail to increase the protective effects of ranolazine in isolated working rat hearts after ischemia and reperfusion. Ferrandon P, Chaylat C, Armstrong JM EUR J PHARMACOL 1990 183 328-329
10. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB EUR J CLIN PHARMACOL 1990 38 111 -114
11. Antianginal activity tested in 14 patients with chronic unstable angina pectoris using a treadmill exercise test. Results suggest that ranolazine may significantly increase exercise time before the onset of symptoms without altering heart rate or blood pressure.
12. New anti-ischaemic drugs: Cytoprotective action with no primary haemodynamic effects. Boddeke E, Hugtenburg J, Jap W, Heynis J, Van Zwieten P TRENDS PHARMACOL SC1198910 397-400
13. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Allely MC, Alps BJ BR J PHARMACOL 1990 99 5-6
14. The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog. Allely MC, Alps BJ BR J PHARMACOL 1988 93 2 375-382
15. Ranolazine. DRUGS FUTURE 1988 13 9837-838
16. New anti-Ischaemic drugs: Cytoprotective action with no primary haemodynamic effects. Boddeke E, Hugtenburg J, Jap W. Heynis J, Van Zwieten P TRENDS PHARMACOL SC11989 10 10397-400
17. A new therapeutic approach to myocardial ischemia Repine CJ JMYOCARD ISCHEMIA 1993 5 9-10
18. A new approach to treat myocardial ischemia? Pouleur H, Hue L, Hariow BJ, Rousseau MF CIRCULATION 1989 80 II52
19. Novel antianginal agent increases exercise duration and pressure-rate product in patients receiving diltiazem or blocker. Essamri B, Rousseau MF, D'Hondt AM, Ahn S, Detry JM, Pouleur H EUR HEART J1992 13 97
20. A comparison of the effects of ranolazine, lidoflazine and dipyridamole on the uptake and catabolism of adenosine in human red blood cells in vitro. Ferrandon P, Barcelo B, Armstrong JM FUNDAM CLIN PHARMACOL 1991 5 456
21. Novel metabolic modulator ranolazine selectively improves diastolic function in heart failure. Rousseau MF, Van Eyll C, Van Mechelen H, Hariow BJ, Pouleur H CIRCULATION 1992 86 4 Suppl 1 I375
22. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics In patients with angina pectoris. Rousseau MF, Cocco G, Bouvy T, Cheron P, William CJ, Detry JMR, Pouleur H CIRCULATION 1992 86 4 Suppl 1 1714
23. Double-blind efficacy and safety study of a novel antiischemic agent, ranolazine, versus placebo In patients with chronic stable angina pectoris. Thadani U, Fenney L, Chiang YK, Ezekowitz M CIRCULATION'1994 90 2 726-734
24. A well-conducted, double-blind clinical efficacy and safety study in patients with chronic stable angina pectoris showing no significant benefits from ranolazine treatment after 4 weeks, despite lacking a cross-over treatment phase.
25. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR CARDIOVASC RES 19942881231-1237
26. Ranolazine. DRUGS FUTURE 1993 18 9 872
27. Modulation of a,-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M J CARDIOVASC PHARMACOL 1993 21 6 869-873
28. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Clarke B, Spedding M, Patmore L, McCormack JG BR J PHARMACOL 1993 109 3 748750
29. Metabolic management of ischaemic heart disease.
30. Chierchia SL, Fragasso G EUR HEART J1993 14 Supp G 2-5
31. Ranolazine. DRUGS FUTURE 1994 19 9 882
32. Effects of ranolazine on left ventricular regional diastolic function in ischémie heart disease. Hayashida W, Van Eyll C, Rousseau MF, Pouleur H CARDIOVASC DRUGS THER 1993 7 Suppl 2 Abs 269
33. Effect of ranolazine on Infarct size In a canine model of regional myocardial ischemia/reperfusion. Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR J CARDIOVASC PHARMACOL 1994 24 6 921-928
34. Ranolazine: antianginal efficacy may result from modifying j myocardial metabolism. DRUGS THERPERSPECT1994 7
35. Ranolazine. Syntax CLIN TRIALS MONITOR 1995 4 8 P36 i
36. Kissel licenses Roche's ranolazine. SCRIP 1996 2090/2091 12
37. Kissel makes licensing agreement with Syntex for ranolazine. PHARMA JP/V19961482 10
38. The antianginal agent ranozaline is a weak inhibitor of the respiratory Complex I, but with greater potency in broken or uncoupled that In coupled mitochondria. Wyatt KM, Skene C, Veitch K, Hue L, McCormack JG BIOCHEM PHARMACOL 1995 50 10 15991606
39. Effects of ranolazine on exercise capacity of rats with chronic heart failure induced by myocardial infarction. Aaker A, McCormack JG, Hirai T, Musch Tl J CARDIOVASC PHARMACOL 1996283353-362
40. Analyst report. CV Therapeutics Inc COMPANY COMMUNICATION 1996 November 05
41. Novel anti-arrhythmics, restenosis drugs in preclinicals at CV Therapeutics. EMERGING PHARMACEUTICALS1996 5 12 7-8
42. CV therapeutics seeking partner to support ranolazine SR phase II trials. FDD REPORTS PINK SHEET 1996 58 49 T&G8-T&G9
43. DRUG DEV PIPELINE 1996 1 8 1
44. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: Potential for pharmacological interventions. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG CARDIOVASC RES 1997 33 2 243-257
45. Effects of ranolazine on L-type calcium channel currents in guinea pig single ventricular myocytes. Allen TJA, Chapman RABRJ PHARMACOL 1996 118 2 249-254
46. Cardiovascular Therapeutic Review: Roche. HOARE GOVETT PHARM SECTOR RES 1997 May
47. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. McCormack JG, Baracos VE, Barr R, Lopaschuk GD JAPPL PHYSIOL 1996 81 2 905-910
48. Ranolazine Increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. Clarke B, Wyatt KM, McCormack JG J MOL CELL CARDIOL 1996 28 2 341-350
49. Ranolazine stimulates glucose oxidation in normoxic, ischémie, and reperfused ischémie rat hearts. McCormack JQ, Barr RL, Wdff AA, LopaschukGD C/RCUMT/CW199693 1 135-142
50. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Penman AD, Eadie J, Herron WJ, Reilly MA, Rush WR, Liu Y RAPID COMMUN MASS SPECTROM1995 9 14 1418-1430
51. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease? Rizzon P, Iliceto S, Marangelli V CARDIOLOGIA 1995 40 10 717-720
52. Pharmacologie therapy of angina pectoris. Zavecz JH, Bueno O J LA STATE MED SOC1995 147 5 208-210 - 213-216
53. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. Smith WB, Chrysant S, Garland WT, Parker TS, Walpole HT, Mokatrin A, Gennevois D, Pepine CJ, Syntex Ranolazine Study Group J AM COLL CARDIOL 1995 Spec Iss 24A-25A
54. Ranolazine. DRUGS FUTURE 1994 19 9 882
55. Effects of ranolazine on left ventricular regional diastolic function in patients with ischémie heart disease.
56. Hayashida W, van Eyil C, Rousseau MF, Pouleur H CARDIOVASC DRUGS THER1994 8 5 741-747
57. A clinical study using angiographie techniques to assess the effects of ranolazine on heart function in 15 patients with a previous myocardial infarction. Some improvements in regional heart function demonstrated.
58. [Therapeutic application of myocardial cytoprotection]. A aplicacao terapeutica da citoproteccao mlocardica. Ribeiro C REV PORT CARDIOL 1994 13 9 669-670
59. Cardioprotective effects of ranolazine (RS-43285) on isolated rabbit hearts during ischemia-reperfusion. Gralinski MR, Black SC, Kilgore KS, Chou AY, Denardis M, Lucchesi BR FASEB J1994 8 4-5 A559
60. Ranolazine: Antianginal therapy with a novel mechanism: Placebo controlled comparison versus atenolol.
61. Rousseau MF, Visser FG, Bax JJ, Dubrey S, Cocco G, Pouleur H, Harris SR, Wolff AA EUR HEART J1994 15 Abs Suppl 95
62. Adjunctive pharmacologie therapy for acute myocardial infarction. Pepine CJ CLIN CARDIOL 1994 17 1 Suppl 110-114
63. Ranolazine. DRUGS FUTURE 1993 18 9 872
64. Effects of novel metabolic modulator ranolazine on exercise tolerance and left ventricular filing dynamics in patients with angina pectoris. Cocoo G, Rousseau MF, Bouvy T, Cheron P, William C, Detry JM, Pouleur H EUR HEART J 1992 13 Abs Suppl 97
65. Ranolazine inhibits cAMP accumulation induced by ischaemia and Isoprenaline but not that induced by forskolin in rat hearts In vitro. Ferrandon P, Chaylat C, Michel D, Armstrong JM J MOL CELL CARDIOL 1992 24 Suppl 4 S56
66. The anti-lschaemic effects of ranolazine in guinea-pig heart are associated with increases in active pyruvate dehydrogenase. Clarke B, McCormack JG. Spedding M J MOL CELL CARDIOL 1992 24 Suppl 4 S52
67. Ranolazine. DRUGS FUTURE 199015 9 964-965
68. Novel antianginal agent increases exercise duration and pressure-rate product in patients receiving diltiazem or -blocker. Essamri B, Rousseau MF, D'Hondt AM, Ahn S, Detry JM, Pouleur H CIRCULATION 1990 82 4 Suppl 3 III 393 Ranolazine shown to increase exercise duration and heart pressure rate production in angina patients receiving diltiazem or blocker therapy.
69. Ranolazine but not allopurinol or dipyridamole reduces the ventricular acidosis and lactate produced by low perfusion flow in isolated rat hearts. Ferrandon P, Chaylat C, Fligiel E, Armstrong JM THERAPIE 1990 45 1
70. Metabolic pathways modulation a new approach to treat myocardial ischemia? Pouleur H, Hue L, Hartow BJ, Rousseau MF CIRCULATION 1989 80 4 Suppl 2 II52
71. Direct HPLC resolution of aminoalcohol tazifylline ranolazine sotalol enantiomers. Delee E, Le Garrec L, Jullien I, Beranger S, Pascal JC, Pinhas H CHROMATOGRAPHIA 1987 24 0 357-359
72. Ranolazine. DRUGS FUTURE 1996 21 9 973
73. Pilot study hemodynamic effects of ranolazine in the myocardial infarcted rat Corder CN, Samkutty G FASEB J 1996 103A428
74. Ranolazine. DRUGS FUTURE 1995 20 9 965
75. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selectedion monitoring. Herron WJ, Eadie J, Penman AD J CHROMATOGRA 1995 712 1 55-60
76. CV Therapeutics licenses late-stage anti-anginal drug from Syntex (USA), an affiliate of Roche Holding Ltd. CV
77. Therapeutics Inc PRESS RELEASE 1996 April 01
78. CV Therapeutics begins phase III trial of angina drug.
79. Therapeutics Inc PRESS RELEASE 1997 October 08
80. Clinical trials update. SCRIP 1997 2278 23
81. Effects of ranolazine on ischémie threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Bagger JP, Botker HE, Thomassen A, Nielsen TT CARDIOVASC DRUGS THER1997 11 3 479-484
82. Angina, myocardial hibernation and trimetazidine.
83. JacksonG INT J CLIN PRACT1997 51 6347
84. The pathophysiology of peripheral arterial disease: Rational targets for drug intervention. Cooke JP VASC MED 199723227-230
85. CVT-510 selected as 1998 IND candidate for the treatment of atrial arrhythmias. CV Therapeutics Inc PRESS RELEASE 1998 January 16
86. DRUG DEV PIPELINE 1997 2 11 1 -4
87. Biogen/CV Therapeutics CVT-124 development will target diuretic-resistant FDC REPORTS PINK SHEET 1998 60 7 T&G9
88. CV Therapeutics reports 1997 financial results. CV
89. Therapeutics Inc PRESS RELEASE 1998 March 31
90. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. Smith WB, Chrysant S, Garland WT, Parker TS, Walpole HT, Mokatrin A, Gennevois D, Pepine CJ, Syntex Ranolazine Study Group J AM COLL CARDIOL 1995 0 Spec Iss 24A-25A
91. Catalytica Pharmaceuticals to provide clinical trial material for CV Therapeutics Ranolazine phase III angina studies. Catalytica Pharmaceuticals Inc PRESS RELEASE 1998 August 05
92. CV Therapeutics Initiates International sites for ranolazine pivotal phase III trial. CV Therapeutics Inc PRESS RELEASE 1999 January 29
93. CV Therapeutics reports 1998 financial results. CV
94. Therapeutics Inc PRESS RELEASE 1999 March 2
95. Innovation in Cardiovascular Drugs, London, UK.
96. Ahmed T IDDB MEETING REPORT 1999 March 3-4
97. Innovation in Cardiovascular Drugs (Part II) London, UK. Henkel T IDDB MEETING REPORT 1993 March 3-4
98. A novel metabolic modulator for the treatment of angina. McCormack JG, Stanley WC, Wolff AA GEN PHARMACOL 19985639-645
99. Is modulation of myocardial metabolism as effective as blockade in exercise-induced angina? Rousseau MF, Visser FG, Bax JJ, Noble MIM, Dubrey S, Cocco G, Pasteuning WH, Williams G, Dodds P, Pouleur H JAM COLL CARDIOL 1994 23 Suppl A 268
100. CV Therapeutics reports 1999 first quarter financial results. CV Therapeutics Inc PRESS RELEASE 1999 April 22
101. Beneficial effects of ranolazine on the myocardial derangements induced by palmitoyl-L-carnitine in the isolated, perfused rat heart Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y JPN J PHARMACOL 1999 79 Suppl I P220
102. CV Therapeutics completes treatment in pivotal phase III ranolazine trial. CV Therapeutics Inc PRESS RELEASE 1999 June 2
103. CV Therapeutics announces CVT-510 phase I clinical data supports decision to move into phase II trials. CV
104. Therapeutics Inc PRESS RELEASE 1999 June 24
105. CV Therapeutics announces publication of phase II ranolazine data in the American Journal of Cardiology. CV
106. Therapeutics Inc PRESS RELEASE 1999 June 30
107. CV Therapeutics initiates second pivotal phase III clinical trial for ranolazine. CV Therapeutics Inc PRESS RELEASE 1999 July 07
108. CV Therapeutics reports 1999 second quarter financial results. CV Therapeutics Inc PRESS RELEASE 1999 July 23
109. CV Therapeutics announces initial results from phase III ranolazine trial drug would be first in new class to potentially treat angina, a serious heart disease affecting 7.2 million Americans. CV Therapeutics Inc PRESS RELEASE 1999 August 18
110. Innovation in cardiovascular drugs: Drug development portfolios: 3-4 March 1999, London UK. Ahmed T IDRUGS 1999 2 5 400-402
111. Therapeutic innovation. Henkel T IDRUGS 1999 2 5 403404
112. Methods of treatment using ranolazine and related piperazine derivatives. Dow RJ, Ferrandon P OFFICIAL GAZETTE USPTO199912224
113. Metabolic intervention for the ischémie and postIschemic heart. Svedjeholm R, Hakanson E, Szabo Z WIEN KLIN WOCHENSCHR1999 111 13 501 -511 i
114. Antianginal effects of ranolazine in various j experimental models of angina. Wang JX, Muruyama K, Murakami M, Endo T, Komatsu H, Akahane M ARZNEIMITTELFORSCHUNG 1999 49 3 193-199
115. Ranolazine: An antiischemic drug with a novel mechanism of action. Hara A, Matsumura H, Muruyama K, Hashizume H, Ushikubi F, Abiko Y CARDIOVASC DRUG REV 1999 17 1 58-74
116. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
117. Repine CJ, Wolff AA AMJCARDIOL 1999 84 1 46-50
118. [Treating ischémie heart disease by pharmacologically improving cardiac energy metabolism]. Traiter les cardiopathies ischemiques par une amelioration pharmacologique du métabolisme énergétique cardiaque.
119. Lopaschuk G D PRESSE MED 1998 27 39 2100-2104
120. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Matsumura H, Hara A, Hashizume H, Muruyama K, Abiko Y JPN J PHARMACOL1998 77 1 31-39
121. Treating ischémie heart disease by pharmacologically improving cardiac energy metabolism. Lopaschuk GD AM J CARDIOL 1998 82 5A 14K-17K
122. CV Therapeutics licenses Roche's ranolazine. SCRIP 1996212310
123. Annual Report - CV Therapeutics - 1997. CV
124. Therapeutics Inc ANNUAL REPORT" 1998 April
125. CV Therapeutics seeks $70M through offering. BIOWORLD WEEK 1999 7 37 2